Radiofrequency Ablation Devices market Size Worth USD 13.20 Billion in 2032 | Emergen Research

Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global Radiofrequency Ablation (RFA) devices market size was USD 4.30 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.0% during the forecast period. Rising prevalence of chronic pain disorders and cardiovascular diseases (CVDs) and increasing healthcare Expenditure, and are key factors driving market revenue growth.

RFA, a minimally invasive procedure suitable for various conditions, including cardiac diseases, cancer, and pain management, is gaining prominence. Cardiovascular Diseases (CVDs) alone account for 17.9 million annual deaths globally, making them the leading cause of mortality. The efficacy, ease of use, and safety of Radiofrequency Ablation (RFA), especially in treating diseases like cancer and cardiac arrhythmias, contribute to its widespread adoption.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2631

Technological Advancements Driving Market Growth

Innovations in RF ablation devices, particularly the integration of multimodality imaging and treatment planning, stand out as key drivers for market growth. The use of various imaging modalities such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and ultrasound enhances the precision of RFA procedures. Computational models predicting temperature distribution and areas at risk contribute to improved patient outcomes, fostering the market's expansion.

Challenges in Healthcare Costs and Trends in Device Development

Despite its effectiveness, the high cost associated with RFA procedures poses a challenge, limiting access for patients without adequate health insurance or financial resources. Addressing healthcare disparities in access to RFA treatments is crucial for broader adoption. A notable trend in device development is the simultaneous determination of transmural effect achievement, enhancing precision and effectiveness, particularly in treating arrhythmias. Real-time monitoring of tissue heating and transmurality allows for more controlled and efficient ablations, showcasing the industry's commitment to improving patient outcomes.

Segment-wise Insights: Cardiology & Cardiac Rhythm Dominate

Application Segment:

On the basis of application, the global Radiofrequency Ablation (RFA) devices market is segmented into surgical oncology, pain management, cardiology & cardiac rhythm management, cosmetology, gynecology, and others. The cardiology & cardiac rhythm segment accounted for largest market share in the global RFA devices market in 2022 due to increasing preference for minimally invasive procedures, particularly catheter ablation. Patients with cardiac arrhythmias, including conditions such as Atrioventricular Re-Entrant Tachycardia (AVRT) and Atrial Fibrillation (AF), are increasingly opting for catheter ablation as it offers a less invasive alternative to traditional surgical methods.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2631

End-Use Insights:

On the basis of end-use, the global Radiofrequency Ablation (RFA) devices market is segmented into hospitals, Ambulatory Surgery Centers (ASCs), and research laboratories. The research laboratory segment is expected to register the fastest market growth rate in the global RFA devices market over the forecast period.  This is because these laboratories serve as hubs for innovation and research, leading to the development of more efficient and precise Radiofrequency Ablation (RFA) devices. As technology continues to evolve, research laboratories are expected to refine existing equipment, create new applications, and explore novel techniques, resulting in more effective, efficient, and safe RFA procedures.

Regional Insights:

North America accounted for largest market share in the global Radiofrequency Ablation (RFA) devices market in 2022 due to rising popularity of radiofrequency ablation as a non-pharmacological approach to pain management. Patients and healthcare providers in the region have shown an increasing reluctance toward traditional pain relief methods involving pharmaceuticals. As concerns about the opioid crisis and side effects of medications persist, Radiofrequency Ablation (RFA) has emerged as a safer and more effective option for addressing chronic pain.

Europe is expected to account for considerably large market share in the global Radiofrequency Ablation (RFA) devices market during the forecast period. This is due to increasing effectiveness and minimally invasive nature in treating conditions such as Barrett's esophagus and dysplastic epithelium in the esophagus.

Scope of Research

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2631

Major Companies and Competitive Landscape

The global RFA devices market is moderately fragmented, with many large and medium-sized players accounting for majority of market revenue. Major businesses are using a variety of tactics, making mergers and acquisitions, strategic agreements, and contracts, as well as creating, experimenting with, and introducing more efficient RFA devices solutions.

Some major players included in the global RFA devices market report are:

• Johnson & Johnson
• Smith & Nephew Plc.
• Abbott Laboratories
• Stryker Corporation
• Medtronic Plc.
• Boston Scientific Corporation
• Baylis Medical Company Inc.
• Avanos Medical Inc.
• AngioDynamics Inc.
• RF Medical Co. Ltd.
• AtriCure Inc.
• MedSphere International Inc.
• Diros Technology Inc.
• Hologic, Inc.
• Stryker
• Arthrex
• Misonix, Inc.
• Elekta
• Mantisse
• MedWaves, Inc.

Strategic Development

• On 17 October, 2023 Johnson & Johnson (J&J) MedTech is undergoing a two-year restructuring program for its DePuy Synthes orthopedic business. The restructuring aims to exit less profitable markets and product lines, enhancing profitability after a 2.6% sales growth in Q3. This program is expected to conclude by the end of 2025, with a cost estimate of USD 700 million to USD 800 million. While the restructuring can lead to modest revenue disruption over the next two years, J&J believes it will accelerate future growth and profitability. The CEO expressed optimism, especially regarding knee-related improvements, with an emphasis on securing a prominent position in high-growth orthopedic segments.
• On 19 May, 2023 Abbott gained FDA approval for its TactiFlex Ablation Catheter, Sensor Enabled, touted as the world's first flexible-tip ablation catheter with contact force technology. This catheter, which integrates with Abbott's EnSite X EP System, is designed to enhance the precision of visualizing heart anatomy, reducing procedure times and improving safety. The flexible tip incorporates a laser-cut pattern that adapts upon contact with the heart, directing fluid to targeted tissue. This design improves the positioning accuracy of catheter, ensuring consistent and effective therapy. The approval comes amid increasing competition in the cardiac ablation space, with companies such as J&J's Biosense Webster and Medtronic.

Segments Covered in Report

For the purpose of this report, Emergen Research has segmented the global RFA devices market on the basis of product, application, end-use, and region:

• Product Outlook (Revenue, USD Billion; 2019-2032)
  • RF Generators
  • Disposables
    1. Cannulas
    2. Needles
  • Reusables
    1. Probes
    2. Electrodes

• Application Outlook (Revenue, USD Billion; 2019-2032)
  • Surgical Oncology
  • Pain Management
  • Cardiology & Cardiac Rhythm Management
  • Cosmetology
  • Gynecology
  • Others
    1.  
• End-use Outlook (Revenue, USD Billion; 2019-2032)
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Research Laboratories

• Regional Outlook (Revenue, USD Billion; 2019–2032)
  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. France
    3. UK
    4. Italy
    5. Spain
    6. Benelux
    7. Rest of Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • Middle East & Africa
    1. Saudi Arabia
    2. UAE
    3. South Africa
    4. Turkey
    5. Rest of Middle East & Africa

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/radiofrequency-ablation-devices-market

Curated Reports You Shouldn't Miss: Dive In Now!

Peripheral Vascular and Biliary Stents Market, By Product Type (Peripheral Vascular Stents and Biliary Stents), By Material (Metal Stents and Polymer Stents), By End-Use, and By Region Forecast to 2032

Hemodialysis and Peritoneal Dialysis Market, By Type, By Product (Devices and Consumables), By Modality, By Disease Type, By End-Use (Home Settings, Hospitals and Dialysis Centers, and Others), and By Region Forecast to 2032

Lancets Market, By Product (Standard Lancets, Safety Lancets, and Specialty Lancets), By Application (Blood Glucose Testing, Cholesterol Testing, and Others), By End-Use (Hospitals and Clinics, Homecare, and Others), and By Region Forecast to 2032

Veterinary Computed Tomography Scanner Market, By Type (Stationary Multi Slice CT Scanners and Portable CT Scanners), By Animal Type (Livestock and Companion), By Application, By End-Use, and By Region Forecast to 2032

Coronary Stents Products Market, By Product Type (Bare Metal Stents, Drug-Eluting Stents, and Bioresorbable Stents), By End-Use (Hospitals, Cardiac Centers, and Others), and By Region Forecast to 2032

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights